Mark Cuban’s Cost-Plus Pricing Is Breaking Pharma’s Patent Playbook
Mark Cuban’s “cost-plus” pricing isn’t just a pricing tweak—it’s a direct challenge to the patent playbook that’s defined Big Pharma for decades.
For years, the industry’s story has been consistent: innovation is expensive, patents are necessary to rec…
Mark Cuban’s Cost-Plus Pricing Is Breaking Pharma’s Patent Playbook Read Post »
